Impact Factor
3.37
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.37
601 total citations
h5-index
29
h5 depth signal
Cited share
75.7%
199 of 263
Total citations
601
Citation footprint
Metric signal
2.90
External metric anchor
Self-citation
1.0%
6 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
429
China
268
Italy
159
United Kingdom
93
Germany
80
Citing Fields of Research
Immunology
934
Oncology
345
Immunotherapy
264
Allergies
157
Lung Cancer
157
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,434
Articles tracked across the journal lifetime
Indexed publication set
263
199 cited publications
Last 12 months
106
8.8 publications/month
Open access share
17.9%
19 OA publications in the last year
Leading citing country
United States
429 citing publications
Leading citing field
Immunology
934 citing publications
Latest tracked publication
11 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Jan. 2009-
v1n1, Jan. 2009-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Broad Categories
Allergy and Immunology
Therapeutics
Immunology
Allergies
Musculoskeletal Disorders
Lung Cancer
Urology
MeSH Descriptors
Immunotherapy
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1080/1750743x.2026.2746875
Open DOI
Real-world efficacy and safety of neoadjuvant immunochemotherapy in patients with triple-negative breast cancer
03
04
DOI 10.1080/1750743x.2026.2742742
Open DOI
Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
1. Guillain–Barre syndrome (GBS) is an acute inflammatory polyradiculoneuropathy, with an annual global incidence of 1–2 per 100,000, and is one of the leading causes of acute flaccid paralysis [1,...
05
DOI 10.1080/1750743x.2026.2743429
Open DOI
Liquid–liquid phase separation-related gene can predict prognosis and influence immune microenvironment in acute myeloid leukemia
06
DOI 10.1080/1750743x.2026.2743426
Open DOI
Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma
1. Hepatocellular carcinoma (HCC) constitutes the predominant form of primary liver malignancy and ranks as the third major contributor to cancer-associated mortality across the world [1]. China ac...
07
08
DOI 10.1080/1750743x.2026.2738337
Open DOI
Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer
09
DOI 10.1080/1750743x.2026.2735709
Open DOI
Addressing socioeconomic barriers to immunotherapy access for non-small cell lung cancer in Japan
10
Bibliographical & Catalog Notes
Description based on: Vol. 1, no. 1 (Jan. 2009); title from cover.
Latest issue consulted: Vol. 1, no. 1 (Jan. 2009).
Also issued online.